Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Tailored Home Intervention Reduces Falls by 33% in Stroke Patients

Key Takeaway
Implement tailored home interventions to reduce fall rates in stroke patients.

This randomized controlled trial evaluated a multidisciplinary, home-based intervention designed to reduce falls in stroke survivors. Conducted across three states in Australia, the study included 370 participants over 50 years old, within five years post-stroke, who were ambulatory and discharged from formal rehabilitation. The intervention group received a six-month program involving functional exercises, home fall hazard reduction, and community mobility coaching, delivered by physiotherapist and occupational therapist teams. The primary outcome was the rate of falls over 12 months, which showed a significant 33% reduction in the intervention group compared to usual care (incidence rate ratio 0.67, 95% CI 0.48 to 0.94; P=0.02). However, there was no significant difference in the proportion of participants experiencing a fall (absolute risk reduction 0.03, 95% CI -0.07 to 0.13; P=0.52). Secondary outcomes favored the intervention group, with improvements in community participation (mean difference 3%, 95% CI 1% to 6%; P=0.02), self-efficacy (mean difference 0.6, 95% CI 0.2 to 1.0; P=0.004), mobility (fast walking speed: mean difference 0.13 m/s, 95% CI 0.06 to 0.19; P<0.001), and balance (Step Test: mean difference 0.06 steps/s, 95% CI 0.01 to 0.12; P=0.03). No significant safety concerns or adverse events were reported. Clinically, this intervention suggests a viable strategy to enhance mobility and reduce fall risk in community-dwelling stroke survivors.

AI Accuracy Review: 9/10 · Auto-published
View Original Abstract ↓
OBJECTIVE: To investigate the effectiveness of a multidisciplinary, home based, tailored intervention to reduce falls after stroke. DESIGN: Two armed, randomised trial. SETTING: Three states in Australia. PARTICIPANTS: People within 5 years of stroke, aged >50 years, discharged from formal rehabilitation to the community, and able to walk 10 m across flat ground with or without an aid. Those with moderate-to-severe receptive aphasia or walking speed >1.4 m/s without falls in the previous year were excluded. INTERVENTION: Over 6 months, the experimental group received a habit forming functional exercise, home fall hazard reduction, and goal directed community mobility coaching; the control group received usual care. Physiotherapist and occupational therapist dyadic teams worked collaboratively to deliver the intervention. MAIN OUTCOME MEASURES: The primary outcome was rate of falls over 12 months. Secondary outcomes were proportion of participants having a fall, community participation, self-efficacy, balance, mobility, physical activity, activities of daily living, depression, and health related quality of life. RESULTS: Between August 2019 and December 2023, 370 people with stroke were enrolled. At 12 months, a significant between group difference was seen in the rate of falls in favour of the experimental group, representing a 33% reduction in falls (incidence rate ratio 0.67, 95% confidence interval (CI) 0.48 to 0.94; P=0.02). No significant between group difference was seen in the number of participants having a fall (absolute risk reduction 0.03, 95% CI -0.07 to 0.13; P=0.52). The main between group differences in favour of the experimental group were in community participation (Late Life Function and Disability Instrument disability limitation: mean difference 3% (95% CI 1% to 6%); P=0.02), self-efficacy (mean difference 0.6 (0.2 to 1.0); P=0.004), mobility (fast walking speed: mean difference 0.13 (0.06 to 0.19) m/s (P<0.001); preferred walking speed: 0.06 (0.02 to 0.10) m/s (P=0.02)), and balance (Step Test: mean difference 0.06 (0.01 to 0.12) steps/s; P=0.03). CONCLUSION: A tailored intervention prevented falls in community dwelling, ambulatory people with stroke. The decrease in the rate of falls was underpinned by clinically worthwhile improvements in self-efficacy, mobility, community participation, and balance. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12619001114134.
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…